Interv Akut Kardiol 2012; 11(5-6): 202-210

Significance of pharmacological intervention for heart rate in treating cardiovascular disease

Jan Bultas
Farmakologický ústav, 3. lékařská fakulta UK, Praha

Heart rate is an independent factor affecting ischaemic load in patients with angina pectoris and the rate of cardiovascular events in

patients with chronic heart failure. The dependence of all-cause as well as cardiovascular mortality on baseline heart rate has been

documented in long-term monitoring of healthy population. During pharmacological intervention as part of prophylaxis for myocardial

ischaemia in patients with angina pectoris, a reduction in ischaemic load has been documented for both treatment with beta blockers

and treatment with ivabradine. Whether the rates of cardiovascular events and mortality are also favourably affected in treatment with

ivabradine is being investigated in the SIGNIFY study. The treatment of chronic heart failure with drugs with negative chronotropic

effect – beta blockers and ivabradine – favourably affected cardiovascular morbidity and mortality. Pharmacological intervention for

increased heart rate has thus become one of standard therapeutic strategies in treating a number of cardiovascular diseases.

Keywords: heart rate, myocardial ischaemia, heart failure, beta blockers, ivabradine, verapamil

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bultas J. Significance of pharmacological intervention for heart rate in treating cardiovascular disease. Interv Akut Kardiol. 2012;11(5-6):202-210.
Download citation

References

  1. Rosano GM, Fini M, Caminiti G, et al. Cardiac metabolism in myocardial ischemia. Curr Pharm Des. 2008; 14(25): 2551-2562. Go to original source... Go to PubMed...
  2. Ohman J, Kudira R, Albinsson S, et al. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun. 2012; 418(4): 754-758. Go to original source... Go to PubMed...
  3. Pachucki J, Burmeister LA, Larsen PR. Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Circ Res. 1999; 85(6): 498-503. Go to original source... Go to PubMed...
  4. Jose AD, Collison D. The normal range and determinants of the intrinsic heart rate in man. Cardiovasc Res. 1970; 4(2): 160-167. Go to original source... Go to PubMed...
  5. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984; 12; 226(4671): 180-182. Go to original source... Go to PubMed...
  6. Dominguez-Rodriguez A, Blanco-Palacios G, Abreu-Gonzalez P. Increased heart rate and atherosclerosis: potential implications of ivabradine therapy. J Cardiol. 2011; 3(4): 101-104. Go to original source... Go to PubMed...
  7. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001; 104(13): 1477-1482. Go to original source... Go to PubMed...
  8. Morcet JF, Safar M, Thomas F, et al. Associations between heart rate and other risk factors in a large French population. J Hypertens. 1999; 17(12 Pt 1): 1671-1676. Go to original source... Go to PubMed...
  9. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension. 1999; 33(1): 44-52. Go to original source... Go to PubMed...
  10. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993; 125(4): 1148-1154. Go to original source... Go to PubMed...
  11. Tverdal A, Hjellvik V, Selmer R. Heart rate and mortality from cardiovascular causes: a 12 year follow-up study of 379,843 men and women aged 40-45 years. Eur Heart J. 2008; 29(22): 2772-2781. Go to original source... Go to PubMed...
  12. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I (f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005; 26(23): 2529-2536. Go to original source... Go to PubMed...
  13. Deanfield JE, Detry JM, Sellier P, et al. Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. J Am Coll Cardiol. 2002; 40(5): 917-925. Go to original source... Go to PubMed...
  14. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008; 153(8): 1589-1601. Go to original source... Go to PubMed...
  15. Cullington D, Goode KM, Clark AL, et al. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail. 2012 May 22. Go to original source... Go to PubMed...
  16. McAlister FA, Wiebe N, Ezekowitz JA. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009; 150(11): 784-794. Go to original source... Go to PubMed...
  17. Cochrane B, Quinn S, Walters H, et al. Investigating the adverse respiratory effects of beta-blocker treatment: six years of prospective longitudinal data in a cohort with cardiac disease. Intern Med J. 2011 Jul 25, Epub.
  18. Daly CA, Clemens F, Sendon JL, et al. Inadequate control of heart rate in patients with stable angina: results from the European heart survey. Postgrad Med J. 2010; 86(1014): 212-217. Go to original source... Go to PubMed...
  19. Liu J, Noble PJ, Xiao G, et al. Role of pacemaking current in cardiac nodes: insights from a comparative study of sinoatrial node and atrioventricular node. Prog Biophys Mol Biol. 2008; 96(1-3): 294-304. Go to original source... Go to PubMed...
  20. Bucchi A, Tognati A, Milanesi R, et al. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006; 572(Pt 2): 335-346. Go to original source... Go to PubMed...
  21. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I (f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005; 26(23): 2529-2536. Go to original source... Go to PubMed...
  22. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007; 67(3): 393-405. Go to original source... Go to PubMed...
  23. Werdan K, Ebelt H, Nuding S, et al. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012; 101(5): 365-373. Go to original source... Go to PubMed...
  24. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372(9641): 807-816. Go to original source... Go to PubMed...
  25. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744): 875-885. Go to original source... Go to PubMed...
  26. Cucherat M, Borer JS. Reduction of resting heart rate with antianginal drugs: review and meta-analysis. Am J Ther. 2012; 19(4): 269-280. Go to original source... Go to PubMed...
  27. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012.
  28. Lacinová L. T-type calcium channel blockers - new and notable. Gen Physiol Biophys. 2011; 30(4): 403-409. Go to original source... Go to PubMed...
  29. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010; 376(9744): 886-894. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.